肿瘤淋巴细胞反应与DNA错配修复缺陷可识别与患者结局相关的II/III期结直肠癌亚型
该前瞻性队列纳入1265例II/III期结直肠癌患者,依据肿瘤浸润淋巴细胞(TIL)和DNA错配修复(MMR)状态分为四种亚型,并在602例独立队列中验证。TIL-low/dMMR与TIL-low/pMMR患者5年无病生存期均较差,TIL/MMR分型对预后的预测优于NCCN高危特征、基因组和转录组亚型。
要点
- 基于TIL和MMR状态的四种亚型中,TIL-low/dMMR与TIL-low/pMMR预后相似且均较差。
- dMMR通常被认为是预后良好的标志,但其预后意义取决于TIL的存在。
- TIL/MMR分型对预后的预测优于NCCN高危特征、基因组和转录组亚型。
核心结论
- TIL/MMR分型可识别与不同结局相关的II/III期结直肠癌亚型,dMMR状态的良好预后依赖于TIL的存在。
- 基于TIL/MMR亚型的预后判断优于组织病理学、基因组和转录组亚型。
研究设计与样本
- 前瞻性队列纳入1265例II/III期结直肠癌患者,检测TIL/MMR状态和BRAF/KRAS突变,其中142例确定共识分子亚型(CMS)状态。
- 在602例患者的独立队列中对TIL/MMR状态与5年无病生存期(DFS)的关联进行验证。
主要发现
- 基于TIL和MMR状态分为四种亚型:TIL-low/pMMR占61.3%,TIL-high/pMMR占14.8%,TIL-low/dMMR占8.6%,TIL-high/dMMR占15.2%。
- 与预后最好的TIL-high/dMMR肿瘤相比,TIL-low/dMMR肿瘤(HR=3.53;95%CI=1.88至6.64;多因素P<0.001)和TIL-low/pMMR肿瘤(HR=2.67;95%CI=1.47至4.84;多因素P=0.001)的DFS均较差。
- TIL-low/dMMR与TIL-low/pMMR肿瘤患者结局相似,TIL-high/pMMR肿瘤生存率居中,上述发现在独立队列中得到验证。
- TIL/MMR状态对预后的预测比NCCN高危特征更显著,且优于基因组亚型(dMMR、pMMR/BRAFwt/KRASwt、pMMR/BRAFmut/KRASwt、pMMR/BRAFwt/KRASmut)和转录组亚型(CMS 1-4)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tumour-infiltrating lymphocyte (TIL) response and deficient DNA mismatch repair (dMMR) are determinants of prognosis in colorectal cancer. Although highly correlated, evidence suggests that these are independent predictors of outcome. However, the prognostic significance of combined TIL/MMR classification and how this compares to the major genomic and transcriptomic subtypes remain unclear. DESIGN: A prospective cohort of 1265 patients with stage II/III cancer was examined for TIL/MMR status and BRAF/KRAS mutations. Consensus molecular subtype (CMS) status was determined for 142 cases. Associations with 5-year disease-free survival (DFS) were evaluated and validated in an independent cohort of 602 patients. RESULTS: Tumours were categorised into four subtypes based on TIL and MMR status: TIL-low/proficient-MMR (pMMR) (61.3% of cases), TIL-high/pMMR (14.8%), TIL-low/dMMR (8.6%) and TIL-high/dMMR (15.2%). Compared with TIL-high/dMMR tumours with the most favourable prognosis, both TIL-low/dMMR (HR=3.53; 95% CI=1.88 to 6.64; Pmultivariate<0.001) and TIL-low/pMMR tumours (HR=2.67; 95% CI=1.47 to 4.84; Pmultivariate=0.001) showed poor DFS. Outcomes of patients with TIL-low/dMMR and TIL-low/pMMR tumours were similar. TIL-high/pMMR tumours showed intermediate survival rates. These findings were validated in an independent cohort. TIL/MMR status was a more significant predictor of prognosis than National Comprehensive Cancer Network high-risk features and was a superior predictor of prognosis compared with genomic (dMMR, pMMR/BRAFwt /KRASwt , pMMR/BRAFmut /KRASwt , pMMR/BRAFwt /KRASmut ) and transcriptomic (CMS 1-4) subtypes. CONCLUSION: TIL/MMR classification identified subtypes of stage II/III colorectal cancer associated with different outcomes. Although dMMR status is generally considered a marker of good prognosis, we found this to be dependent on the presence of TILs. Prognostication based on TIL/MMR subtypes was superior compared with histopathological, genomic and transcriptomic subtypes.
引用
- Williams DS, Mouradov D, Jorissen RN, et al. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut. 2018. PMID: 29382774. doi:10.1136/gutjnl-2017-315664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。